Please Wait.....
Report
North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Market Report I 2023-07-27 I 224 Pages I The Insight Partners
The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is expected to reach US$ 315.74 billion by 2028. It is estimated to register a CAGR of 13.1% from 2022 to 2028.
Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market
According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents both scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the North Americas have developed new technologies for treating rare diseases and developing groundbreaking therapies. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the North America biopharmaceuticals market expansion.
North America Biopharmaceuticals Market Overview
The North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of cancer, growing product introduction in the region, and technological advancements in biopharmaceuticals. The biopharmaceuticals industry is at a pivotal stage in medical research with tremendous potential to further revolutionize the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C. The rising burden of chronic diseases and increased investment in research and development activities in the US are driving the market in the region. The biopharmaceuticals industry makes important contributions to the US economy. The US leads the world in most R&D investment and innovation indices. As of 2020, biopharmaceutical companies in the United States have more than 3,400 drugs in clinical development, accounting for almost half of the estimated 8,000 drugs worldwide (of which 1,100 are being developed to treat various types of cancer). The biopharmaceuticals industry makes important contributions to the US economy by creating direct economic activities and supporting indirect activities. Pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added in 2018. Biotech R&D facilities accounted for another 0.23%. Data from the Centers for Disease Control and Prevention (CDC), updated in July 2022, shows that coronary artery disease is the most common form of heart disease. Approximately 20.1 million adults aged 20 and older in the United States suffer from this condition. According to CDC data, someone suffers a heart attack every 40 seconds, and nearly 805,000 people in the US suffer a heart attack annually. All these factors are expected to boost the North America biopharmaceuticals market growth significantly during the forecast period.
North America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)
North America Biopharmaceuticals Market Segmentation
The North America biopharmaceuticals market is segmented into product type, application, and country.
Based on product type, the North America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the North America biopharmaceuticals market.
The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.
Based on application, the North America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the North America biopharmaceuticals market.
Based on country, the North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. In 2022, the US accounted for the largest share of the North America biopharmaceuticals market.
AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading companies operating in the North America biopharmaceuticals market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Biopharmaceuticals Market - by Product Type
1.3.2 North America Biopharmaceuticals Market - by Application
1.3.3 North America Biopharmaceuticals Market - by Country
2. North America Biopharmaceuticals Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Biopharmaceuticals Market - Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert's Opinion
5. North America Biopharmaceuticals Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. Biopharmaceuticals Market - North America Analysis
6.1 North America Biopharmaceuticals Market Revenue Forecast and Analysis
7. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type
7.1 Overview
7.2 North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8. North America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application
8.1 Overview
8.2 North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis
9.1 Overview
9.1.1 North America: Biopharmaceuticals Market, by Country
9.1.1.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
10. North America Biopharmaceuticals Market - Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
11. Company Profiles
11.1 Amgen Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 AbbVie Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Eli Lilly and Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Johnson & Johnson
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Thermo Fisher Scientific Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 AGC Biologics AS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Lonza Group AG
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 WuXi Biologics Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Table 2. United States Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 3. United States Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 4. United States Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 5. United States Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 6. United States Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 7. United States Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 8. United States Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 9. United States Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 10. United States Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 19. Canada Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 20. Canada Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 21. Canada Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 25. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 26. Mexico Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 27. Mexico Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 28. Mexico Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 29. Mexico Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 30. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 31. Mexico Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
Table 33. Recent Inorganic Growth Strategies in the North America biopharmaceuticals market
Table 34. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Biopharmaceuticals Market Segmentation
Figure 2. North America Biopharmaceuticals Market, by Country
Figure 3. North America Biopharmaceuticals Market Overview
Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in North America Biopharmaceuticals Market
Figure 5. US Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts\' Opinion
Figure 8. North America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
Figure 9. North America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
Figure 10. North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 12. Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 13. Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 14. Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 15. Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 16. Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 18. Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 19. Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Enterokinase: north America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 51. Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 53. North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
Figure 54. Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 57. Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. North America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 63. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 64. United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 66. Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security